| 1392 |
National Cancer Institute |
Html |
en |
Childhood Rhabdomyosarcoma Treatment (PDQ®)–Health Professional Version |
Treatment of children with rhabdomyosarcoma often includes chemotherapy, radiation therapy, and surgery. For pediatric embryonal, alveolar, and anaplastic rhabdomyosarcoma, learn about the signs, diagnosis, prognosis, treatment regimens, and clinical trials in this expert-reviewed summary. |
| soft tissue | 0.790585 |
| intermediate risk rhabdomyosarcoma | 0.445041 |
| rhabdomyosarcoma cases | 0.455822 |
| childhood rhabdomyosarcoma | 0.593521 |
| rhabdomyosarcoma patients | 0.545472 |
| children | 0.493211 |
| intergroup rhabdomyosarcoma studies | 0.517745 |
| alveolar rhabdomyosarcoma patients | 0.515716 |
| rhabdomyosarcoma | 0.96522 |
| Int J Radiat | 0.504093 |
| advanced extremity rhabdomyosarcoma | 0.456564 |
| Radiat Oncol Biol | 0.739922 |
| childhood rhabdomyosarcoma incidence | 0.473829 |
| pediatric rhabdomyosarcoma patients | 0.456936 |
| patients | 0.603999 |
| spindle cell rhabdomyosarcoma | 0.473635 |
| intermediate-risk rhabdomyosarcoma | 0.519136 |
| Rhabdomyosarcoma Study-IV experience | 0.444462 |
| biliary tract rhabdomyosarcoma | 0.443533 |
| Rhabdomyosarcoma Study Group | 0.470276 |
| extremity rhabdomyosarcoma | 0.461496 |
| adult rhabdomyosarcoma patients | 0.499141 |
| soft tissue sarcoma | 0.736147 |
| et al. | 0.806046 |
| Intergroup Rhabdomyosarcoma Study | 0.799018 |
|
| intergroup rhabdomyosarcoma study-iv | 0.552013 |
| differentiated embryonal rhabdomyosarcoma | 0.474756 |
| PUBMED Abstract | 0.447631 |
| Pediatr Blood Cancer | 0.665669 |
| intermediate-risk rhabdomyosarcoma patients | 0.477987 |
| nonmetastatic rhabdomyosarcoma | 0.468047 |
| alveolar rhabdomyosarcoma cases | 0.455418 |
| gene-negative alveolar rhabdomyosarcoma | 0.459372 |
| typical embryonal rhabdomyosarcoma | 0.456569 |
| metastatic rhabdomyosarcoma | 0.445146 |
| group iii rhabdomyosarcoma | 0.483139 |
| Abstract | 0.667848 |
| Clin Oncol | 0.743964 |
| Intergroup Rhabdomyosarcoma Study-II | 0.496765 |
| Oncol Biol Phys | 0.753212 |
| rhabdomyosarcoma experience relapse | 0.449214 |
| tissue sarcoma committee | 0.500618 |
| orbital rhabdomyosarcoma | 0.45917 |
| alveolar rhabdomyosarcoma | 0.600282 |
| lymph node | 0.533988 |
| cell rhabdomyosarcoma patients | 0.482049 |
| intergroup rhabdomyosarcoma | 0.827615 |
| embryonal rhabdomyosarcoma | 0.685831 |
| oncology group | 0.614164 |
|
CLICK HERE |
| 1417 |
National Cancer Institute |
Html |
en |
Stomach (Gastric) Cancer Prevention (PDQ®)–Health Professional Version |
Risk factors for stomach (gastric) cancer include certain health conditions (e.g., atrophic gastritis, pernicious anemia, H. pylori infection), genetic factors (e.g., Li-Fraumeni syndrome), or environmental factors (e.g., diet, smoking). Review the evidence on these and other risk factors and interventions to prevent stomach cancer in this expert-reviewed summary. |
| randomized placebo-controlled trial | 0.595383 |
| gastric adenomatous polyps | 0.679902 |
| experimental animal models | 0.575229 |
| infected family members | 0.578256 |
| antioxidant dietary supplements | 0.574787 |
| H. pylori | 0.663672 |
| annual incidence rates | 0.588818 |
| secondary prevention measures | 0.572741 |
| age-adjusted incidence rate | 0.59463 |
| statistically significant reduction | 0.578799 |
| combined antioxidant groups | 0.572868 |
| H. pylori infection | 0.650947 |
| high H. pylori | 0.585004 |
| family members | 0.581961 |
| gastric cancer mortality | 0.686327 |
| endoscopic resection techniques | 0.578064 |
| placebo group | 0.585452 |
| chemoprevention trial | 0.590009 |
| H. pylori-infected family | 0.583244 |
| Li Fraumeni syndrome | 0.58425 |
| intestinal metaplasia | 0.628781 |
| advanced premalignant lesions | 0.570945 |
| protective effects | 0.575049 |
| low selenium content | 0.586292 |
|
| statistically significant effect | 0.623477 |
| Beta Carotene trial | 0.587524 |
| United States | 0.702911 |
| gastric cancer incidence. | 0.664051 |
| precancerous gastric lesions. | 0.647932 |
| 5-year survival rate | 0.635247 |
| gastric cancer cases | 0.674324 |
| gastric cancers | 0.625749 |
| gastrointestinal cancers | 0.575893 |
| H. pylori-infected people | 0.581367 |
| overall 5-year survival | 0.57409 |
| beta carotene | 0.671292 |
| small randomized trial | 0.598139 |
| gastric cancer | 0.97116 |
| gastric adenocarcinoma. | 0.625249 |
| eradication therapy | 0.572355 |
| Chinese medical journal | 0.572216 |
| vitamin supplementation | 0.570623 |
| statistically significant regression | 0.573687 |
| chronic atrophic gastritis | 0.586209 |
| gastric cancer. | 0.610162 |
| close family members. | 0.576811 |
| family history | 0.58364 |
| steady incidence rates | 0.587586 |
|
CLICK HERE |
| 1602 |
National Cancer Institute |
Html |
en |
Spirituality in Cancer Care (PDQ®)–Patient Version |
Spiritual or religious beliefs and practices help patients, families, and caregivers cope with cancer and spiritual distress. Learn how religious and spiritual needs are met during treatment and improve a patient’s quality of life in this expert-reviewed summary. |
| cancer treatment | 0.522404 |
| religious beliefs | 0.681568 |
| different spiritual needs | 0.447208 |
| PDQ Spirituality | 0.401148 |
| PDQ cancer information | 0.786944 |
| health care team | 0.714879 |
| spiritual coping | 0.379369 |
| clinical trials | 0.650438 |
| health care providers | 0.685151 |
| cancer information summary | 0.61546 |
| clinical trial | 0.49863 |
| cancer care | 0.577956 |
| breast cancer prevention | 0.397717 |
| Important spiritual practices | 0.424705 |
| PDQ summaries | 0.403088 |
| patients | 0.717217 |
| cancer patients | 0.380258 |
| latest published information | 0.382717 |
| NCI’s PDQ | 0.403017 |
| seriously ill patients | 0.414358 |
| NCI PDQ cancer | 0.529841 |
| spiritual beliefs | 0.417232 |
| family caregivers | 0.485214 |
| cancer prevention | 0.40291 |
|
| spiritual assessment | 0.396713 |
| religious well-being | 0.397613 |
| Cancer Information Service | 0.434582 |
| PDQ Supportive | 0.390304 |
| spiritual well-being | 0.502278 |
| patient | 0.48208 |
| treatment clinical trials | 0.384067 |
| National Cancer Institute | 0.634076 |
| PDQ documents | 0.389821 |
| health care | 0.824046 |
| Palliative Care Editorial | 0.492644 |
| spiritual concerns | 0.49013 |
| new treatment | 0.40429 |
| advanced cancer | 0.407938 |
| Cancer Care page | 0.435587 |
| PDQ database | 0.398527 |
| Care Editorial Board | 0.494972 |
| PDQ summary | 0.556329 |
| cancer clinical trials | 0.438523 |
| cancer information summaries | 0.448303 |
| comprehensive cancer information | 0.448414 |
| cancer | 0.990441 |
| specific religious beliefs | 0.408892 |
| spiritual issues | 0.481168 |
|
CLICK HERE |
| 1744 |
National Cancer Institute |
Html |
en |
Fluoridated Water |
A fact sheet that reviews research about the possibility of a connection between fluoridated water and cancer. |
| human epidemiologic data | 0.594773 |
| Health Service report | 0.593262 |
| fluoride | 0.975933 |
| naturally occurring element | 0.597937 |
| Water Fluoridation Statistics | 0.623696 |
| current fluoridated water | 0.628477 |
| Disease Control | 0.669272 |
| detectable cancer risk | 0.614332 |
| human epidemiologic studies | 0.60115 |
| human epidemiologic | 0.621471 |
| community water fluoridation | 0.640412 |
| recent population-based studies | 0.592374 |
| public drinking water | 0.647792 |
| fluoridated drinking water | 0.666776 |
| cumulative fluoride exposure | 0.764553 |
| drinking water quality | 0.646469 |
| sodium fluoride | 0.715451 |
| Ingested Fluoride | 0.834058 |
| water fluoridation | 0.705423 |
| fluoride concentration | 0.727809 |
| fewer dental caries | 0.600428 |
| cancer case records | 0.605334 |
| water cause cancer | 0.645853 |
| fluoride benefits | 0.721837 |
| drinking water supplies | 0.676312 |
|
| Health Effects | 0.629934 |
| fluoride exposure | 0.797986 |
| bone tumors | 0.594815 |
| United States | 0.643827 |
| cancer registry data | 0.601829 |
| National Toxicology Program | 0.663407 |
| Environmental Health Sciences | 0.59604 |
| fluoridated water | 0.77455 |
| water treatment records | 0.619812 |
| fluoride intake | 0.729368 |
| bone fluoride levels | 0.775983 |
| drinking water | 0.947407 |
| cancer death records | 0.605385 |
| Subsequent interview studies | 0.59194 |
| public water systems | 0.633935 |
| fluoride accumulates | 0.757179 |
| fluoride content | 0.748381 |
| tooth decay | 0.600449 |
| water supply | 0.612845 |
| National Research Council | 0.659684 |
| parts water | 0.59656 |
| Public Health Service | 0.66604 |
| cancer risk | 0.653999 |
| et al | 0.614927 |
|
CLICK HERE |
| 1797 |
National Cancer Institute |
Html |
es |
Tensión postraumática relacionada con el cáncer (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca de la tensión postraumática y los síntomas relacionados en los pacientes con cáncer, sobrevivientes del cáncer y miembros de la familia. Se discuten la evaluación y el tratamiento de estos síntomas. |
| múltiples desencadenantes | 0.698347 |
| Visuals Online | 0.436428 |
| siguientes aspectos | 0.505084 |
| Physician Data Query | 0.684121 |
| eventual reaparición | 0.766932 |
| PDQ Tensión | 0.667559 |
| antidepresivos tricÃclicos | 0.472229 |
| Pensamientos aterradores | 0.527245 |
|
| largo plazo | 0.915335 |
| llamada reacción | 0.465322 |
| incidente perturbador | 0.510371 |
| múltiples situaciones | 0.480298 |
| desencadenantes perturbadores | 0.501006 |
| National Cancer Institute | 0.465776 |
| siguientes riesgos | 0.441057 |
| Instituto Nacional | 0.530266 |
|
CLICK HERE |
| 1924 |
National Cancer Institute |
Html |
es |
Tratamiento del cáncer de nasofaringe (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento del cáncer de nasofaringe. |
| tratamiento.Ciertas formas | 0.524228 |
| glándula tiroides | 0.523181 |
| estadios iva | 0.528495 |
| Neck Cancer | 0.521392 |
| siguientes procedimientos | 0.7107 |
| estadio ii | 0.666414 |
| rayos x | 0.537811 |
| pequeñas marcas | 0.522053 |
| enlace drugs approved | 0.539586 |
| National Cancer Institute | 0.517706 |
| siguientes riesgos | 0.513715 |
| Instituto Nacional | 0.534665 |
|
| malla ayuda | 0.523662 |
| hormonas tiroideas | 0.523525 |
| PDQ Tratamiento | 0.533313 |
| ganglios linfáticos detrás | 0.99863 |
| Physician Data Query | 0.572904 |
| estadio iii | 0.585657 |
| espacio parafarÃngeo | 0.772191 |
| cáncer.ampliar radioterapia | 0.583477 |
| glándula tiroidea | 0.524738 |
| Estadio IVC | 0.548072 |
| Estadio IVA | 0.547554 |
| siguientes estadios | 0.604168 |
|
CLICK HERE |
| 1989 |
National Cancer Institute |
Html |
es |
Cuidados médicos de apoyo en niños (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca de la peculiaridad de los asuntos que surgen durante y después del tratamiento en los niños con cáncer, y como sobrevivientes adultos de cáncer. |
| etapa final | 0.974283 |
| posibles efectos tardÃos | 0.445113 |
| células madre | 0.448459 |
| adultos jóvenes | 0.631616 |
| personas jóvenes | 0.478657 |
| posibles tratamientos | 0.424654 |
| siguientes aspectos | 0.421705 |
| cáncer causa estrés | 0.501532 |
| apoyo social escaso | 0.437899 |
| siguientes tipos | 0.415041 |
| largo plazo | 0.418906 |
| efectos tardÃos | 0.530812 |
| familia reaccionarán | 0.418853 |
| National Cancer Institute | 0.415958 |
| siguientes riesgos | 0.411551 |
|
| siguientes maneras | 0.446878 |
| Instituto Nacional | 0.427962 |
| sÃntomasEl trastorno | 0.423462 |
| Cuidado paliativo | 0.412419 |
| distintos miembros | 0.413316 |
| tratamiento ayuda | 0.457106 |
| suicidioUn número | 0.419685 |
| siguientes efectos | 0.419968 |
| posibles efectos | 0.465562 |
| Physician Data Query | 0.458553 |
| sistema nervioso central | 0.433857 |
| mayores probabilidades | 0.421125 |
| Estados Unidos | 0.416849 |
| mejores tratamientos | 0.417691 |
|
CLICK HERE |
| 15485 |
National Cancer Institute |
Html |
null |
NCI-Related Cancer Moonshot Activities |
This page describes a number of activities NCI is involved in that support the goals of the Cancer Moonshot. |
|
|
CLICK HERE |
| 16682 |
National Cancer Institute |
Html |
es |
714-X (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos sobre el uso del 714-X como tratamiento para personas con cáncer. Nota: La información contenida en este sumario ya no se actualiza y se ofrece solo con fines de consulta. |
| suficiente información | 0.416844 |
| 714-X ayuda | 0.603181 |
| Centro Nacional | 0.441981 |
| New Hampshire Avenue | 0.428509 |
| Drug Administration | 0.417778 |
| NCI Best Case | 0.453667 |
| historial médico | 0.42385 |
| datos bibliográficos pubmed | 0.43091 |
| siguientes preguntas | 0.416986 |
| siguientes riesgos | 0.421888 |
| seguro médico | 0.417314 |
| Instituto Nacional | 0.654 |
| vitamina e | 0.42491 |
|
| Salud Complementaria | 0.462517 |
| Visuals Online | 0.421729 |
| complementarias revisa | 0.430487 |
| Physician Data Query | 0.526604 |
| Estados Unidos | 0.798049 |
| libre uso | 0.424103 |
| página manejo | 0.420327 |
| ¿El tratamiento | 0.432404 |
| ¿Los beneficios | 0.418313 |
| juntos cam | 0.417388 |
| siguientes formas | 0.425809 |
| Series Program | 0.418184 |
| medicina complementaria | 0.936374 |
|
CLICK HERE |
| 16862 |
National Cancer Institute |
Html |
es |
Terapia Gerson (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos sobre el uso de la terapia Gerson como tratamiento para personas con cáncer. Nota: La información contenida en este sumario ya no se actualiza y se ofrece solo con fines de consulta. |
| diet therapy after | 0.308285 |
| Gerson therapies | 0.323938 |
| cancer treatment | 0.320934 |
| low sodium diet | 0.305659 |
| Regional Cancer Therapy | 0.308916 |
| Exp Med Surg | 0.311537 |
| Sin embargo | 0.310104 |
| cancer therapy | 0.362986 |
| San Diego | 0.316933 |
| Fifty Cases | 0.313326 |
| Unconventional Cancer Treatments | 0.306866 |
| malignant tumors | 0.306376 |
| preliminary report | 0.312542 |
| CA Cancer | 0.311309 |
| dieta gerson | 0.372353 |
| Gerson Research Organization | 0.324799 |
| Instituto Nacional | 0.324032 |
| suero lácteo | 0.306238 |
| Walker M | 0.306008 |
| régimen gerson | 0.39009 |
| PDQ Terapia Gerson | 0.32794 |
| Estados Unidos | 0.310808 |
| método gerson | 0.324606 |
| Rev Gastroenterol | 0.312306 |
| Nueva York | 0.309059 |
|
| Charlotte Gerson Straus | 0.324657 |
| gerson therapy | 0.37388 |
| Liebow C | 0.304873 |
| Physiol Chem Phys | 0.339192 |
| Hospital Gerson | 0.32512 |
| Gerson M | 0.587193 |
| clinical experimentation | 0.312661 |
| PDQ Régimen Gonzalez | 0.309341 |
| Gerson C | 0.344712 |
| National Cancer Institute | 0.306378 |
| combined dietary | 0.306376 |
| Kensington Publishing Corp | 0.310101 |
| vitamina b12 | 0.310902 |
| diet therapy | 0.393116 |
| New York | 0.309477 |
| advanced cancer | 0.355076 |
| accessed april | 0.313019 |
| Amazing Nutritional Program | 0.311171 |
| enzimas pancreáticas | 0.373196 |
| Dietary considerations | 0.313324 |
| Gerson Institute | 0.453889 |
| Other Illnesses | 0.306194 |
| Max Gerson | 0.406639 |
| terapia gerson | 0.96769 |
|
CLICK HERE |